Analysis of BRAF mutation in primary and metastatic melanoma

被引：85

作者：

Libra, M

Malaponte, G

Navolanic, PM

Gangemi, P

Bevelacqua, V

Proietti, L

Bruni, B

Stivala, F

Mazzarino, MC

Travali, S

McCubrey, JA

机构：

[1] Univ Catania, Dept Biomed Sci, I-95124 Catania, Italy

[2] Univ Catania, Dept Internal Med & Systemic Pathol, Div Occupat Hlth, I-95124 Catania, Italy

[3] Univ Catania, Dept Orthodont, I-95124 Catania, Italy

[4] Vittorio Emanuele II Hosp, Dept Pathol, Catania, Italy

[5] E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC USA

[6] E Carolina Univ, Brody Sch Med, Leo W Jenkins Canc Ctr, Greenville, NC USA

来源：

CELL CYCLE | 2005年 / 4卷 / 10期

关键词：

BRAF; melanoma;

D O I：

10.4161/cc.4.10.2026

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Mutation of BRAF has been proposed to contribute to melanoma development. However, it remains unclear whether or not BRAF mutation is associated with any particular stage of melanoma progression. Tumor biopsy specimens from patients with melanoma were analyzed to determine whether the frequency of BRAF mutation in metastatic melanoma differed from primary melanoma. BRAF mutation was present in 15 of 23 (61%) patients with primary melanoma and in 7 of 12 (58%) patients with metastatic melanoma. These results suggest that BRAF mutation in melanoma is most likely to occur prior to the development of metastatic disease.

引用

页码：1382 / 1384

页数：3

共 20 条

[1]

Brose MS, 2002, CANCER RES, V62, P6997

[2] Clinical significance of BRAF mutations in metastatic melanoma [J].

Chang D.Z. ;

Panageas K.S. ;

Osman I. ;

Polsky D. ;

Busam K. ;

Chapman P.B. .

Journal of Translational Medicine, 2 (1)

[3] Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention [J].

Chang, F ;

Steelman, LS ;

Lee, JT ;

Shelton, JG ;

Navolanic, PM ;

Blalock, WL ;

Franklin, RA ;

McCubrey, JA .

LEUKEMIA, 2003, 17 (07) :1263-1293

[4]

Chang FM, 2003, INT J ONCOL, V22, P469

[5] Melanoma genetics and the development of rational therapeutics [J].

Chudnovsky, Y ;

Khavari, PA ;

Adams, AE .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (04) :813-824

[6] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[7]

Dong JL, 2003, CANCER RES, V63, P3883

[8] Absence of BRAF mutations in UV-protected mucosal melanomas [J].

Edwards, RH ;

Ward, MR ;

Wu, H ;

Medina, CA ;

Brose, MS ;

Volpe, P ;

Lee, SN ;

Haupt, HM ;

Martin, AM ;

Herlyn, M ;

Lessin, SR ;

Weber, BL .

JOURNAL OF MEDICAL GENETICS, 2004, 41 (04) :270-272

[9]

Gorden A, 2003, CANCER RES, V63, P3955

[10] The role of B-RAF in melanoma [J].

Gray-Schopfer, VC ;

Dias, SD ;

Marais, R .

CANCER AND METASTASIS REVIEWS, 2005, 24 (01) :165-183

← 1 2 →